These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26042928)

  • 1. Caruncular Leishmaniasis--An Unusual Case.
    Badri Prasad B; Shakya A; Poonam L; Smriti K
    Orbit; 2015; 34(4):232-3. PubMed ID: 26042928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Progressive Dysphonia and Dysphagia due to Laryngeal Leishmaniasis.
    Renard L; Lemaignen A; Desoubeaux G; Bakhos D
    Am J Trop Med Hyg; 2021 Jun; 105(2):458-460. PubMed ID: 34125697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment for leishmaniasis is 95% effective.
    Bull World Health Organ; 2002; 80(8):688. PubMed ID: 12219169
    [No Abstract]   [Full Text] [Related]  

  • 4. Leishmaniasis.
    Desjeux P
    Nat Rev Microbiol; 2004 Sep; 2(9):692. PubMed ID: 15378809
    [No Abstract]   [Full Text] [Related]  

  • 5. Miltefosine (Impavido) for leishmaniasis.
    Med Lett Drugs Ther; 2014 Sep; 56(1451):89-90. PubMed ID: 25211304
    [No Abstract]   [Full Text] [Related]  

  • 6. Visceral leishmaniasis simulating chronic liver disease: successful treatment with miltefosine.
    Avasthi R; Chaudhary SC; Khanna S
    Indian J Med Microbiol; 2009; 27(1):85-6. PubMed ID: 19172077
    [No Abstract]   [Full Text] [Related]  

  • 7. Miltefosine and cutaneous leishmaniasis.
    Machado PR; Penna G
    Curr Opin Infect Dis; 2012 Apr; 25(2):141-4. PubMed ID: 22248979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laryngeal leishmaniasis in a patient taking inhaled corticosteroids.
    Roberts RM; Mukherjee J; Phillips D
    BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27329097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic adverse effects of miltefosine in the treatment of leishmaniasis: a systematic review.
    Pal B; Atem TD; Kumari S; Murti K; Kumar R; Pandey K; Siddiqui NA; Dhingra S; Chaudhary V
    Cutan Ocul Toxicol; 2024 Sep; 43(3):190-197. PubMed ID: 39023122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Miltefosine for disseminated cutaneous leishmaniasis].
    González LM; Vélez ID
    Biomedica; 2006 Oct; 26 Suppl 1():13-6. PubMed ID: 17361837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.
    Vakil NH; Fujinami N; Shah PJ
    Pharmacotherapy; 2015 May; 35(5):536-45. PubMed ID: 25940658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miltefosine in the treatment of a case of visceral leishmaniasis with renal dysfunction.
    Kumar N; Pandey K; Das VN; Sinha PK; Topno RK; Verma N; Lal CS; Das P; Bhattacharya SK
    Ann Trop Med Parasitol; 2007 Oct; 101(7):649-51. PubMed ID: 17877883
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
    Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
    Stoeckle M; Holbro A; Arnold A; Neumayr A; Weisser M; Blum J
    Acta Trop; 2013 Oct; 128(1):168-70. PubMed ID: 23871798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmaniasis of the nasal cavity: a case report.
    Shareef MM; Trotter MI; Cullen RJ
    J Laryngol Otol; 2005 Dec; 119(12):1015-7. PubMed ID: 16354374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease.
    Mings S; Beck JC; Davidson C; Ondo AL; Shanler SD; Berman J
    Am J Trop Med Hyg; 2009 Jan; 80(1):3-5. PubMed ID: 19141829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.